Geneos Wealth Management Inc. Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Geneos Wealth Management Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,896 shares of the company’s stock after selling 1,074 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Johnson & Johnson were worth $5,626,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Impax Asset Management Group plc boosted its stake in shares of Johnson & Johnson by 7.7% during the 4th quarter. Impax Asset Management Group plc now owns 86,904 shares of the company’s stock worth $13,621,000 after acquiring an additional 6,209 shares in the last quarter. Stiles Financial Services Inc boosted its stake in shares of Johnson & Johnson by 2.1% during the 4th quarter. Stiles Financial Services Inc now owns 18,111 shares of the company’s stock worth $2,840,000 after acquiring an additional 376 shares in the last quarter. Keener Financial Planning LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $40,000. Harbour Trust & Investment Management Co acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $8,774,000. Finally, Hemington Wealth Management raised its position in shares of Johnson & Johnson by 3.4% during the 4th quarter. Hemington Wealth Management now owns 18,384 shares of the company’s stock worth $2,882,000 after purchasing an additional 609 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.0 %

JNJ stock opened at $147.49 on Tuesday. The company has a market cap of $355.42 billion, a price-to-earnings ratio of 10.68, a PEG ratio of 2.48 and a beta of 0.53. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The business has a fifty day simple moving average of $157.07 and a 200-day simple moving average of $155.90. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.35 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. Morgan Stanley cut their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Finally, Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.